Polymorphisms of innate immunity receptors in infection by parasites

Parasite Immunology

Volumn 33, Issue 12, 2011, Pages 643-653

  Villasenor Cardoso M I ^a   Ortega, E ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Innate immunity; Pattern recognition receptors; Polymorphisms

Indexed keywords

C REACTIVE PROTEIN; COMPLEMENT; MANNOSE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 2;

ADAPTIVE IMMUNITY; APOPTOSIS; DNA POLYMORPHISM; GENETIC TRANSCRIPTION; HAPLOTYPE; IMMUNE RESPONSE; INNATE IMMUNITY; MYCOBACTERIUM LEPRAE; NODULARIA; PARASITOSIS; PATTERN RECOGNITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; DISEASE RESISTANCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, INNATE; PARASITIC DISEASES; POLYMORPHISM, GENETIC; RECEPTORS, IMMUNOLOGIC;

EID: 81255147288     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2011.01327.x     Document Type: Review

References (93)

1. Janeway CA & Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
2. Teixeira MM, Almeida IC & Gazzinelli RT. Introduction: innate recognition of bacteria and protozoan parasites. Microbes Infect 2002; 4: 883-886.
3. McGuinness DH, Dehal PK & Pleass RJ. Pattern recognition molecules and innate immunity to parasites. Trends Parasitol 2003; 19: 312-319.
4. Peiser L, Mukhopadhyay S & Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol 2002; 14: 123-128.
5. Feuk L, Carson AR & Scherer SW. Structural variation in the human genome. Nat Rev Genet 2006; 7: 85-97.
6. Marth G, Yeh R, Minton M, et al. Single-nucleotide polymorphisms in the public domain: how useful are they? Nat Genet 2001; 27: 371-372.
7. Sachidanandam R, Weissman D, Schmidt SC, et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001; 409: 928-933.
8. Kang TJ & Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol Med Microbiol 2001; 31: 53-58.
9. Gazzinelli RT & Denkers EY. Protozoan encounters with Toll-like receptor signalling pathways: implications for host parasitism. Nat Rev Immunol 2006; 6: 895-906.
10. Perrigoue JG, Marshall FA & Artis D. On the hunt for helminths: innate immune cells in the recognition and response to helminth parasites. Cell Microbiol 2008; 10: 1757-1764.
11. Garred P. Mannose-binding lectin genetics: from A to Z. Biochem Soc Trans 2008; 36: 1461-1466.
12. Holmskov U, Thiel S & Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21: 547-578.
13. Boldt AB, Luty A, Grobusch MP, et al. Association of a new mannose-binding lectin variant with severe malaria in Gabonese children. Genes Immun 2006; 7: 393-400.
14. Holmberg V, Schuster F, Dietz E, et al. Mannose-binding lectin variant associated with severe malaria in young African children. Microbes Infect 2008; 10: 342-348.
15. de Messias-Reason IJ, Boldt AB, Moraes Braga AC, et al. The association between mannan-binding lectin gene polymorphism and clinical leprosy: new insight into an old paradigm. J Infect Dis 2007; 196: 1379-1385.
16. Garcia-Laorden MI, Pena MJ, Caminero JA, et al. Influence of mannose-binding lectin on HIV infection and tuberculosis in a Western-European population. Mol Immunol 2006; 43: 2143-2150.
17. Koutsounaki E, Goulielmos GN, Koulentaki M, Choulaki C, Kouroumalis E & Galanakis E. Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. J Clin Immunol 2008; 28: 495-500.
18. Segat L, Silva Vasconcelos LR, Montenegro de Melo F, et al. Association of polymorphisms in the first exon of mannose binding lectin gene (MBL2) in Brazilian patients with HCV infection. Clin Immunol 2007; 124: 13-17.
19. Guimaraes V, Guimaraes R, Brandao L, et al. Association between MBL2 gene functional polymorphisms and high-risk human papillomavirus infection in Brazilian women. Hum Immunol 2008; 69: 273-278.
20. Thévenon AD, Leke RG, Suguitan AL, Zhou JA & Taylor DW. Genetic polymorphisms of mannose-binding lectin do not influence placental malaria but are associated with preterm deliveries. Infect Immun 2009; 77: 1483-1491.
21. Boldt AB, Messias-Reason IJ, Lell B, et al. Haplotype specific-sequencing reveals MBL2 association with asymptomatic Plasmodium falciparum infection. Malar J 2009; 8: 97.
22. Szalai AJ. The biological functions of C-reactive protein. Vascul Pharmacol 2002; 39: 105-107.
23. Edberg JC, Wu J, Langefeld CD, et al. Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet 2008; 17: 1147-1155.
24. Eklund C, Huttunen R, Syrjänen J, Laine J, Vuento R & Hurme M. Polymorphism of the C-reactive protein gene is associated with mortality in bacteraemia. Scand J Infect Dis 2006; 38: 1069-1073.
25. Giha HA, Nasr A, Ekström M, et al. Association of a single nucleotide polymorphism in the C-reactive protein gene (-286) with susceptibility to Plasmodium falciparum malaria. Mol Med 2010; 16: 27-33.
26. Nath SK, Harley JB & Lee YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005; 118: 225-234.
27. Brai M, Accardo P & Bellavia D. Polymorphism of the complement components in human pathology. Ann Ital Med Int 1994; 9: 167-172.
28. Blom AM, Bergström F, Edey M, et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008; 180: 6385-6391.
29. Hasegawa K, Tamari M, Shao C, et al. Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004; 115: 295-301.
30. Miyagawa H, Yamai M, Sakaguchi D, et al. Association of polymorphisms in complement component C3 gene with susceptibility to systemic lupus erythematosus. Rheumatology (Oxford) 2008; 47: 158-164.
31. Martens HA, Zuurman MW, de Lange AH, et al. Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity. Ann Rheum Dis 2009; 68: 715-720.
32. Würzner R. Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit? Clin Exp Immunol 2003; 133: 156-159.
33. Cockburn IA, Mackinnon MJ, O'Donnell A, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci USA 2004; 101: 272-277.
34. Thomas BN, Donvito B, Cockburn I, et al. A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa. Genes Immun 2005; 6: 31-36.
35. Thathy V, Moulds JM, Guyah B, Otieno W & Stoute JA. Complement receptor 1 polymorphisms associated with resistance to severe malaria in Kenya. Malar J 2005; 4: 54.
36. Teeranaipong P, Ohashi J, Patarapotikul J, et al. A functional single-nucleotide polymorphism in the CR1 promoter region contributes to protection against cerebral malaria. J Infect Dis 2008; 198: 1880-1891.
37. Franchi L, Warner N, Viani K & Nuñez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009; 227: 106-128.
38. Magalhaes JG, Sorbara MT, Girardin SE & Philpott DJ. What is new with Nods? Curr Opin Immunol 2011; 23: 29-34.
39. Fritz JH, Girardin SE, Fitting C, et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur J Immunol 2005; 35: 2459-2470.
40. Gazouli M, Mantzaris G, Kotsinas A, et al. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J Gastroenterol 2005; 11: 681-685.
41. Brand S, Staudinger T, Schnitzler F, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis 2005; 11: 645-652.
42. Austin CM, Ma X & Graviss EA. Common nonsynonymous polymorphisms in the NOD2 gene are associated with resistance or susceptibility to tuberculosis disease in African Americans. J Infect Dis 2008; 197: 1713-1716.
43. Finney CA, Lu Z, LeBourhis L, Philpott DJ & Kain KC. Disruption of Nod-like receptors alters inflammatory response to infection but does not confer protection in experimental cerebral malaria. Am J Trop Med Hyg 2009; 80: 718-722.
44. Silva GK, Gutierrez FR, Guedes PM, et al. Cutting edge: nucleotide-binding oligomerization domain 1-dependent responses account for murine resistance against Trypanosoma cruzi infection. J Immunol 2010; 184: 1148-1152.
45. Shaw MH, Reimer T, Sánchez-Valdepeñas C, et al. T cell-intrinsic role of Nod2 in promoting type 1 immunity to Toxoplasma gondii. Nat Immunol 2009; 10: 1267-1274.
46. Witola WH, Mui E, Hargrave A, et al. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells. Infect Immun 2011; 79: 756-766.
47. Kumar H, Kawai T & Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34.
48. Drennan MB, Stijlemans B, Van den Abbeele J, et al. The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88 dependent. J Immunol 2005; 175: 2501-2509.
49. Campos MA, Closel M, Valente EP, et al. Impaired production of proinflammatory cytokines and host resistance to acute infection with Trypanosoma cruzi in mice lacking functional myeloid differentiation factor 88. J Immunol 2004; 172: 1711-1718.
50. Muraille E, De Trez C, Brait M, De Baetselier P, Leo O & Carlier Y. Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 2003; 170: 4237-4241.
51. Scanga CA, Aliberti J, Jankovic D, et al. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002; 168: 5997-6001.
52. Adachi K, Tsutsui H, Kashiwamura S, et al. Plasmodium berghei infection in mice induces liver injury by an IL-12- and toll-like receptor/myeloid differentiation factor 88-dependent mechanism. J Immunol 2001; 167: 5928-5934.
53. Kang TJ, Lee SB & Chae GT. A polymorphism in the toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 2002; 20: 56-62.
54. Kang TJ, Yeum CE, Kim BC, You EY & Chae GT. Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology 2004; 112: 674-680.
55. Bochud PY, Hawn TR & Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J Immunol 2003; 170: 3451-3454.
56. Ben-Ali M, Barbouche MR, Bousnina S, Chabbou A & Dellagi K. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients. Clin Diagn Lab Immunol 2004; 11: 625-626.
57. Woehrle T, Du W, Goetz A, et al. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2008; 41: 322-329.
58. Ogus AC, Yoldas B, Ozdemir T, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219-223.
59. Berdeli A, Celik HA, Ozyürek R, Dogrusoz B & Aydin HH. TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med 2005; 83: 535-541.
60. Brown RA, Gralewski JH & Razonable RR. The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus. Clin Infect Dis 2009; 49: e96-e99.
61. Junpee A, Tencomnao T, Sanprasert V & Nuchprayoon S. Association between Toll-like receptor 2 (TLR2) polymorphisms and asymptomatic bancroftian filariasis. Parasitol Res 2010; 107: 807-816.
62. Smirnova I, Poltorak A, Chan EK, McBride C & Beutler B. Phylogenetic variation and polymorphism at the toll-like receptor 4 locus (TLR4). Genome Biol 2000; 1: RESEARCH002.
63. Smirnova I, Hamblin MT, McBride C, Beutler B & Di Rienzo A. Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics 2001; 158: 1657-1664.
64. Schmitt C, Humeny A, Becker CM, Brune K & Pahl A. Polymorphisms of TLR4: rapid genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles. Clin Chem 2002; 48: 1661-1667.
65. Michel O, LeVan TD, Stern D, et al. Systemic responsiveness to lipopolysaccharide and polymorphisms in the toll-like receptor 4 gene in human beings. J Allergy Clin Immunol 2003; 112: 923-929.
66. Erridge C, Stewart J & Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003; 197: 1787-1791.
67. Fagerås Böttcher M, Hmani-Aifa M, Lindström A, et al. A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004; 114: 561-567.
68. Yang IA, Barton SJ, Rorke S, et al. Toll-like receptor 4 polymorphism and severity of atopy in asthmatics. Genes Immun 2004; 5: 41-45.
69. Child NJ, Yang IA, Pulletz MC, et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003; 31: 652-653.
70. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186: 1522-1525.
71. Lorenz E, Mira JP, Frees KL & Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162: 1028-1032.
72. Barber RC, Aragaki CC, Rivera-Chavez FA, Purdue GF, Hunt JL & Horton JW. TLR4 and TNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 2004; 41: 808-813.
73. Montes AH, Asensi V, Alvarez V, et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 2006; 143: 404-413.
74. Mockenhaupt FP, Hamann L, von Gaertner C, et al. Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinical manifestation of malaria during pregnancy. J Infect Dis 2006; 194: 184-188.
75. Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A 2006; 103: 177-182.
76. Verma A, Prasad KN, Gupta RK, et al. Toll-like receptor 4 polymorphism and its association with symptomatic neurocysticercosis. J Infect Dis 2010; 202: 1219-1225.
77. Kropf P, Freudenberg N, Kalis C, et al. Infection of C57BL/10ScCr and C57BL/10ScNCr mice with Leishmania major reveals a role for Toll-like receptor 4 in the control of parasite replication. J Leukoc Biol 2004; 76: 48-57.
78. Kropf P, Freudenberg MA, Modolell M, et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 2004; 72: 1920-1928.
79. Jenkins SJ, Hewitson JP, Ferret-Bernard S & Mountford AP. Schistosome larvae stimulate macrophage cytokine production through TLR4-dependent and -independent pathways. Int Immunol 2005; 17: 1409-1418.
80. Mun HS, Aosai F, Norose K, et al. TLR2 as an essential molecule for protective immunity against Toxoplasma gondii infection. Int Immunol 2003; 15: 1081-1087.
81. Minns LA, Menard LC, Foureau DM, et al. TLR9 is required for the gut-associated lymphoid tissue response following oral infection of Toxoplasma gondii. J Immunol 2006; 176: 7589-7597.
82. Yarovinsky F, Zhang D, Andersen JF, et al. TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science 2005; 308: 1626-1629.
83. Leoratti FM, Farias L, Alves FP, et al. Variants in the toll-like receptor signaling pathway and clinical outcomes of malaria. J Infect Dis 2008; 198: 772-780.
84. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39: 523-528.
85. Ramasawmy R, Cunha-Neto E, Fae KC, et al. Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the Toll-like receptor pathway, is associated with lower risk of developing chronic Chagas cardiomyopathy. J Infect Dis 2009; 199: 1838-1845.
86. Buckland PR. The importance and identification of regulatory polymorphisms and their mechanisms of action. Biochim Biophys Acta 2006; 1762: 17-28.
87. Atik B, Skwor TA, Kandel RP, et al. Identification of novel single nucleotide polymorphisms in inflammatory genes as risk factors associated with trachomatous trichiasis. PLoS One 2008; 3: e3600.
88. Ferwerda B, McCall MB, Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A 2007; 104: 16645-16650.
89. Hamann L, Kumpf O, Schuring RP, et al. Low frequency of the TIRAP S180L polymorphism in Africa, and its potential role in malaria, sepsis, and leprosy. BMC Med Genet 2009; 10: 65.
90. Ferwerda B, Alonso S, Banahan K, et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A 2009; 106: 10272-10277.
91. Tishkoff SA, Varkonyi R, Cahinhinan N, et al. Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance. Science 2001; 293: 455-462.
92. Maizels RM. Parasite immunomodulation and polymorphisms of the immune system. J Biol 2009; 8: 62.
93. Everts B, Smits HH, Hokke CH & Yazdanbakhsh M. Helminths and dendritic cells: sensing and regulating via pattern recognition receptors, Th2 and Treg responses. Eur J Immunol 2010; 40: 1525-1537.